Histone variants and melanoma: facts and hypotheses

Konstantinov, Nikifor K.; Ulff-Møller, Constance J.; Dimitrov, Stéfan

doi:10.1111/pcmr.12467

Cited by 10 publications

(4 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lastly, more complex regulations of gene expression during melanomagenesis depend on histone variants, such as non-allelic isoforms of the conventional histones that are generally coded by distinct genes [69]. Apart from histone H4, the others include a number of variants, and those reported to correlate with melanoma progression are the histone H2A and the macroH2A (mH2A) as well as H2A.Z and H2A.Z.2 variants [70]. Comprehensively, aberrant expression of these histone variants in melanoma cells was correlated with the transcription of key genes implicated in the regulation of affecting cell-cycle dysregulation, increased migratory capacity, and metastatic propensity [71][72][73][74].…”

Section: Histone Modificationsmentioning

confidence: 99%

Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression

Mannavola

D’Oronzo

Cives

et al. 2019

IJMS

View full text Add to dashboard Cite

Cutaneous melanoma shows a high metastatic potential based on its ability to overcome the immune system’s control. The mechanisms activated for these functions vary extremely and are also represented by the production of a number of extracellular vesicles including exosomes. Other vesicles showing a potential role in the melanoma progression include oncosomes and melanosomes and the majority of them mediate tumor processes including angiogenesis, immune regulation, and modifications of the micro-environment. Moreover, a number of epigenetic modifications have been described in melanoma and abundant production of altered microRNAs (mi-RNAs), non-coding RNAs, histones, and abnormal DNA methylation have been associated with different phases of melanoma progression. In addition, exosomes, miRNAs, and other molecular factors have been used as potential biomarkers reflecting disease evolution while others have been suggested to be potential druggable molecules for therapeutic application.

show abstract

Section: Histone Modificationsmentioning

confidence: 99%

Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression

Mannavola

D’Oronzo

Cives

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…The crystallinity of HANPs was calculated using the following Equation 1, where β 002 is the full width at half maximum of the (002). 30,31 X c = (0.24/β 002 ) 3 (1)…”

Section: Characterization Of Hanpsmentioning

confidence: 99%

“…1,2 In the epidermal layer of skin, there are five layers from inside to outside, in which the melanocytes in the basal layer are susceptible to lesions and then transform into melanoma. 3,4 In recent years, melanoma took on the increasing incidence rate and can also be found in mucosa, choroid, and other tissues. [5][6][7][8][9] So far, the general clinical treatment is still surgical resection, accompanied by chemotherapy and immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

<p>The in vitro and in vivo anti-melanoma effects of hydroxyapatite nanoparticles: influences of material factors</p>

Wu¹,

Li²,

Tang³

et al. 2019

IJN

View full text Add to dashboard Cite

Background Treatment for melanoma is a challenging clinical problem, and some new strategies are worth exploring. Purpose The objective of this study was to investigate the in vitro and in vivo anti-melanoma effects of hydroxyapatite nanoparticles (HANPs) and discuss the involved material factors. Materials and methods Five types of HANPs, ie, HA-A, HA-B, HA-C, HA-D, and HA-E, were prepared by wet chemical method combining with polymer template and appropriate post-treatments. The in vitro effects of the as-prepared five HANPs on inhibiting the viability of A375 melanoma cells and inducing the apoptosis of the cells were evaluated by Cell Counting Kit-8 analysis, cell nucleus morphology observation, flow cytometer, and PCR analysis. The in vivo anti-melanoma effects of HANPs were studied in the tumor model of nude mice. Results The five HANPs had different physicochemical properties, including morphology, size, specific surface area (SSA), crystallinity, and so on. By the in vitro cell study, it was found that the material factors played important roles in the anti-melanoma effect of HANPs. Among the as-prepared five HANPs, HA-A with granular shape, smaller size, higher SSA, and lower crystallinity exhibited best effect on inhibiting the viability of A375 cells. At the concentration of 200 μg/mL, HA-A resulted in the lowest cell viability (34.90%) at day 3. All the HANPs could induce the apoptosis of A375 cells, and the relatively higher apoptosis rates of the cells were found in HA-A (20.10%) and HA-B (19.41%) at day 3. However, all the HANPs showed no inhibitory effect on the viability of the normal human epidermal fibroblasts. The preliminary in vivo evaluation showed that both HA-A and HA-C could delay the formation and growth speed of melanoma tissue significantly. Likely, HA-A exhibited better effect on inhibiting the growth of melanoma tissue than HA-C. The inhibition rate of HA-A for tumor tissue growth reached 49.1% at day 23. Conclusion The current study confirmed the anti-melanoma effect of HANPs and provided a new idea for the clinical treatment of melanoma.

show abstract

“…Genes in the retinoblastoma pathway that were identified in the melanoma families of this study were HDAC3, BRD2, MITF, and RUNX2, making them putative candidate genes for melanoma susceptibility. Of these genes, BRD2 is known to be overexpressed in melanoma and the knockdown of BRD2 in melanoma cell lines has resulted in cell cycle arrest by preventing the progression of cells from G1 to S phase [67]. The role of RUNX2 has been evaluated in inducing cell growth, migration and invasion by ShRNA-mediated knock down of RUNX2 in melanoma cell lines.…”

Section: Discussionmentioning

confidence: 99%

A Weights-based variant ranking pipeline for familial complex disorders

Ralli,

Vira,

Robles-Espinoza

et al. 2023

Preprint

View full text Add to dashboard Cite

Identifying genetic susceptibility factors for complex disorders remains a challenging task. We have developed a weights-based pipeline to prioritize variants and genes in collections of small and large pedigrees where genetic heterogeneity is likely, but biological commonalities are plausible. The Weights-based vAriant Ranking in Pedigrees (WARP) pipeline prioritizes variants using 5 weights: disease incidence rate, number of cases in a family, genome fraction shared amongst cases in a family, allele frequency and variant deleteriousness. Weights, except for the population allele frequency weight, are normalized between 0 to 1. Weights are combined multiplicatively to produce family-specific-variant weights that are then averaged across all families in which the variant is observed to generate a multifamily weight. Sorting multifamily weights in descending order creates a ranked list of variants and genes for further investigation. WARP was validated using familial melanoma sequence data from the European Genome-phenome Archive. The pipeline identified variation in known germline melanoma genesPOT1,MITFandBAP1in 4 out of 13 families (31%). Analysis of the other 9 families identified several interesting genes, some of which might have a role in melanoma. WARP provides an approach to identify disease predisposing genes in studies with small and large pedigrees.

show abstract

Histone variants and melanoma: facts and hypotheses

Cited by 10 publications

References 104 publications

Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression

Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression

<p>The in vitro and in vivo anti-melanoma effects of hydroxyapatite nanoparticles: influences of material factors</p>

A Weights-based variant ranking pipeline for familial complex disorders

Contact Info

Product

Resources

About